摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-(5-bromo(3-pyridyloxy))propyl)methylamine | 246137-86-0

中文名称
——
中文别名
——
英文名称
(3-(5-bromo(3-pyridyloxy))propyl)methylamine
英文别名
3-(5-bromopyridin-3-yl)oxy-N-methylpropan-1-amine
(3-(5-bromo(3-pyridyloxy))propyl)methylamine化学式
CAS
246137-86-0
化学式
C9H13BrN2O
mdl
——
分子量
245.119
InChiKey
QAVWYUYGKCUDJO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    13
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    34.2
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (3-(5-bromo(3-pyridyloxy))propyl)methylaminemeso-galactaric acidwater ethanol乙醇 作用下, 以 乙醇 为溶剂, 反应 72.0h, 以to give 983.3 mg (68.8%) of a glassy, beige powder, mp 166-173.5° C.的产率得到(3-(5-Bromo(3-pyridyloxy))propyl)methylamine Hemigalactarate
    参考文献:
    名称:
    PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
    摘要:
    对于易感或患有中枢神经系统疾病等疾病和疾病的患者,通过给予需要此类治疗的患者芳氧基烷基胺类化合物进行治疗,包括吡啶氧基烷基胺和苯氧基烷基胺。示例化合物包括二甲基(2-(3-吡啶氧基)乙基)胺,二甲基(4-(3-吡啶氧基)丁基)胺,2-(3-吡啶氧基)乙基胺,4-(3-吡啶氧基)丁基胺,甲基(3-(5-甲氧基-3-吡啶氧基)丙基)胺,乙基(3-(3-吡啶氧基)丙基)胺,甲基(2-(3-吡啶氧基)乙基)胺,甲基(3-(6-甲基(3-吡啶氧基))丙基)胺,(3-(3-甲氧基苯氧基)丙基)甲基胺,(3-(5-氯(3-吡啶氧基))-1-甲基丙基)甲基胺,二甲基(3-(3-吡啶氧基)丙基)胺,3-(3-吡啶氧基)丙基胺,甲基(4-(3-吡啶氧基)丁基)胺,3-(5-氯-3-吡啶氧基)丙基胺,甲基(3-(5-异丙氧基-3-吡啶氧基)丙基)胺,(3-(5-氯(3-吡啶氧基))丙基)甲基胺,甲基(3-(5-(苯甲氧基)(3-吡啶氧基))丙基)胺,甲基(3-(2-甲基(3-吡啶氧基))丙基)胺,(甲基乙基)(3-(3-吡啶氧基)丙基)胺,苄基(3-(3-吡啶氧基)丙基)胺,环丙基(3-(3-吡啶氧基)-丙基)胺,甲基(1-甲基-3-(3-吡啶氧基)丙基)胺,甲基(3-(3-硝基苯氧基)丙基)胺,1-(3-氯丙氧基)-3-硝基苯,(3-(3-氨基苯氧基)丙基)甲基胺,二甲基(3-(3-(甲基氨基)-丙氧基)苯基)胺,甲基(3-三环[7.3.1.0<5,13>]十二烷氧基丙基)胺,(3-苯并[3,4-d][1,3]二氧杂环戊烷-5-氧基丙基)甲基胺,3-(4-哌啶氧基)吡啶和3-((3S)-3-吡咯烷氧基)吡啶。
    公开号:
    US20010014691A1
  • 作为产物:
    描述:
    3-chloro-1-(5-bromo-pyridin-3-yloxy)propane甲胺氯化钠氯仿Sodium sulfate-III 作用下, 以 甲醇 为溶剂, 反应 4.0h, 以to give 2.07 g of a brown oil的产率得到(3-(5-bromo(3-pyridyloxy))propyl)methylamine
    参考文献:
    名称:
    PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
    摘要:
    对于易感或患有中枢神经系统疾病等疾病和疾病的患者,通过给予需要此类治疗的患者芳氧基烷基胺类化合物进行治疗,包括吡啶氧基烷基胺和苯氧基烷基胺。示例化合物包括二甲基(2-(3-吡啶氧基)乙基)胺,二甲基(4-(3-吡啶氧基)丁基)胺,2-(3-吡啶氧基)乙基胺,4-(3-吡啶氧基)丁基胺,甲基(3-(5-甲氧基-3-吡啶氧基)丙基)胺,乙基(3-(3-吡啶氧基)丙基)胺,甲基(2-(3-吡啶氧基)乙基)胺,甲基(3-(6-甲基(3-吡啶氧基))丙基)胺,(3-(3-甲氧基苯氧基)丙基)甲基胺,(3-(5-氯(3-吡啶氧基))-1-甲基丙基)甲基胺,二甲基(3-(3-吡啶氧基)丙基)胺,3-(3-吡啶氧基)丙基胺,甲基(4-(3-吡啶氧基)丁基)胺,3-(5-氯-3-吡啶氧基)丙基胺,甲基(3-(5-异丙氧基-3-吡啶氧基)丙基)胺,(3-(5-氯(3-吡啶氧基))丙基)甲基胺,甲基(3-(5-(苯甲氧基)(3-吡啶氧基))丙基)胺,甲基(3-(2-甲基(3-吡啶氧基))丙基)胺,(甲基乙基)(3-(3-吡啶氧基)丙基)胺,苄基(3-(3-吡啶氧基)丙基)胺,环丙基(3-(3-吡啶氧基)-丙基)胺,甲基(1-甲基-3-(3-吡啶氧基)丙基)胺,甲基(3-(3-硝基苯氧基)丙基)胺,1-(3-氯丙氧基)-3-硝基苯,(3-(3-氨基苯氧基)丙基)甲基胺,二甲基(3-(3-(甲基氨基)-丙氧基)苯基)胺,甲基(3-三环[7.3.1.0<5,13>]十二烷氧基丙基)胺,(3-苯并[3,4-d][1,3]二氧杂环戊烷-5-氧基丙基)甲基胺,3-(4-哌啶氧基)吡啶和3-((3S)-3-吡咯烷氧基)吡啶。
    公开号:
    US20010014691A1
点击查看最新优质反应信息

文献信息

  • PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
    申请人:——
    公开号:US20010014691A1
    公开(公告)日:2001-08-16
    Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines. Exemplary compounds include dimethyl(2-(3-pyridyloxy)ethylamine, dimethyl(4-(3-pyridyloxy)butyl)amine, 2-(3-pyridyloxy)ethylamine, 4-(3-pyridyloxy)butylamine, methyl(3-(5-methoxy-3-pyridyloxy)propyl)amine, ethyl(3-(3-pyridyloxy)propyl)amine, methyl(2-(3-pyridyloxy)ethyl)amine, methyl(3-(6-methyl(3-pyridyloxy))propyl)amine, (3-(3-methoxyphenoxy)propyl)methylamine, (3-(5-chloro(3-pyridyloxy))-1-methylpropyl)methylamine, dimethyl(3-(3-pyridyloxy)propyl)amine, 3-(3-pyridyloxy)propylamine, methyl(4-(3-pyridyloxy)butyl)amine, 3-(5-chloro-3-pyridyloxy)propyl amine, methyl(3-(5-isopropoxy-3-pyridyloxy)propyl)amine, (3-(5-chloro(3-pyridyloxy))propyl) methylamine, methyl(3-(5-(phenylmethoxy)(3-pyridyloxy))propyl)amine, methyl(3-(2-methyl(3-pyridyloxy))propyl)amine, (methylethyl)(3-(3-pyridyloxy)propyl)amine, benzyl(3-(3-pyridyloxy)propyl)amine, cyclopropyl(3-(3-pyridyloxy)-propyl)amine, methyl(1-methyl-3-(3-pyridyloxy)propyl)amine, methyl(3-(3-nitrophenoxy)propyl)amine, 1-(3-chloropropoxy)-3-nitrobenzene, (3-(3-aminophenoxy)propyl)methylamine,dimethyl (3-(3-(methylamino)-propoxy)phenyl)amine, methyl(3-tricyclo[7.3.1.0<5,13>]tridec-2-yloxypropyl)amine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, 3-(4-piperidinyloxy)pyridine and 3-((3S)-3-pyrrolidinyloxy)pyridine.
    患有或易受中枢神经系统疾病等病症和紊乱的患者,通过向需要的患者施用芳基氧烷胺类化合物进行治疗,包括吡啶氧烷胺和苯氧烷胺。示例化合物包括二甲基(2-(3-吡啶氧基)乙基)胺,二甲基(4-(3-吡啶氧基)丁基)胺,2-(3-吡啶氧基)乙基胺,4-(3-吡啶氧基)丁基胺,甲基(3-(5-甲氧基-3-吡啶氧基)丙基)胺,乙基(3-(3-吡啶氧基)丙基)胺,甲基(2-(3-吡啶氧基)乙基)胺,甲基(3-(6-甲基(3-吡啶氧基))丙基)胺,(3-(3-甲氧基苯氧基)丙基)甲基胺,(3-(5-氯(3-吡啶氧基))-1-甲基丙基)甲基胺,二甲基(3-(3-吡啶氧基)丙基)胺,3-(3-吡啶氧基)丙基胺,甲基(4-(3-吡啶氧基)丁基)胺,3-(5-氯-3-吡啶氧基)丙基胺,甲基(3-(5-异丙氧基-3-吡啶氧基)丙基)胺,(3-(5-氯(3-吡啶氧基))丙基)甲基胺,甲基(3-(5-(苯甲氧基)(3-吡啶氧基))丙基)胺,甲基(3-(2-甲基(3-吡啶氧基))丙基)胺,(甲基乙基)(3-(3-吡啶氧基)丙基)胺,苄基(3-(3-吡啶氧基)丙基)胺,环丙基(3-(3-吡啶氧基)-丙基)胺,甲基(1-甲基-3-(3-吡啶氧基)丙基)胺,甲基(3-(3-硝基苯氧基)丙基)胺,1-(3-氯丙氧基)-3-硝基苯,(3-(3-氨基苯氧基)丙基)甲基胺,二甲基(3-(3-(甲氨基)-丙氧基)苯基)胺,甲基(3-三环七叁.壹.零<5,13>三十二氧基丙基)胺,(3-苯并三.四-壹,三-二氧杂环戊氧基丙基)甲基胺,3-(4-哌啶氧基)吡啶和3-((3S)-3-吡咯啶氧基)吡啶。
  • ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS
    申请人:Targacept, Inc.
    公开号:EP1185513A2
    公开(公告)日:2002-03-13
  • US6441006B2
    申请人:——
    公开号:US6441006B2
    公开(公告)日:2002-08-27
  • US6441007B1
    申请人:——
    公开号:US6441007B1
    公开(公告)日:2002-08-27
  • [EN] PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE<br/>[FR] PREPARATIONS PHARMACEUTIQUES ET LEUR MODES D'UTILISATION
    申请人:——
    公开号:WO1999051216A2
    公开(公告)日:1999-10-14
    [EN] Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines, including pyridyloxylalkylamines and phenoxyalkylamines, such as (3-(3-pyridyloxy)propyl)methylamine and (3-(5-bromo(3-pyridyloxy))propyl)methylamine.
    [FR] Les patients sujets à, ou souffrant, d'états ou de troubles tels que ceux du SNC seront traités par administration en cas de nécessité d'aryloxyalkylamines dont des pyridyloxyalkylamines et des phénoxyalkylamines telles que la (3-(3-pyridyloxy)propyl)méthylamine, et la (3-(5-bromo(3-pyridyloxy))propyl)méthylamine.
查看更多